Oxidation-reduction Homeostasis in Cognitive Impairment Patients After Stroke

July 29, 2019 updated by: Hui-Sheng Chen

Effects of Oxidation-reduction Homeostasis on Cognitive Impairment in Patients With Ischemic Stroke

Cognitive impairment after ischemic stroke can affect not only the social adaptation ability, but also affect the comprehensive rehabilitation of patients. The damage of cognitive impairment after ischemic stroke is not lower than the body function defect after stroke. Many studies have shown that oxidative stress is one of the pathophysiological mechanisms of ischemic cerebrovascular disease. Many studies have reported that the oxidative-reduction of cells plays an important role in the life activities of organisms, affecting the health, aging and death of the organism. In the recent years, some scholars have suggested that post-stroke cognitive impairment may be related to oxidative-reduction homeostasis of the body, but the relevant evidence is lacking and needs to be further explored. Therefore, the purpose of this study is to explore the effect of oxidation-reduction homeostasis on cognitive impairment in patients with ischemic stroke, and provide a theoretical basis for the prevention and treatment of cognitive impairment after ischemic stroke.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Liaoning
      • Shenyang, Liaoning, China, 10016
        • General Hospital of Shenyang Military Region

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Acute ischemic stroke patients in hospital from March, 2018 to September, 2018.

Description

Inclusion Criteria:

  • 40-80 years old;
  • Ischemic stroke for the first time or previous stroke but with no serious sequelae (mRS is 0 -2 points);
  • Time from onset to treatment ≤48 hours;
  • Conscious awareness, and with no obvious aphasia and visual impairment;
  • Signed informed consent by patient self or legally authorized representatives.

Exclusion Criteria:

  • Intracranial hemorrhage or suspected subarachnoid hemorrhage;
  • Transient ischemic attack;
  • Patients with severe mental disorders or language disorders;
  • Patients can not cooperate with evaluators, such as mental illness or dementia;
  • Pregnant women or suckers;
  • Researchers consider patients inappropriate to participate in the registry.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients with post-stroke cognitive impairment
Other: No intervention has been conducted
It is an observational study, and no intervention has been conducted
Patients without post-stroke cognitive impairment
Other: No intervention has been conducted
It is an observational study, and no intervention has been conducted

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Oxidative-reduction homeostasis in acute ischemic stroke patients
Time Frame: 1 day
Reduced glutathione (GSH)/ Oxidized glutathione (GSSG), Superoxide dismutase (SOD), Catalase (CAT), Glutathione Peroxidase (GSH-PX) of acute ischemic stroke patients will be tested.
1 day
Cognitive function in acute ischemic stroke patients
Time Frame: 1 day
Mini Mental Status Examination (MMSE) and Montreal cognitive assessment scale (MoCA) in acute ischemic stroke patients will be evaluated.
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hui-Sheng Chen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2018

Primary Completion (Actual)

December 30, 2018

Study Completion (Actual)

January 1, 2019

Study Registration Dates

First Submitted

April 15, 2018

First Submitted That Met QC Criteria

April 26, 2018

First Posted (Actual)

May 9, 2018

Study Record Updates

Last Update Posted (Actual)

July 31, 2019

Last Update Submitted That Met QC Criteria

July 29, 2019

Last Verified

July 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • k(2017)34

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe